Adamed Pharma is a Polish research- and patent based pharmaceutical and biotechnology company with 100 percent Polish capital.


Established in 1986, today it employs almost 2500 people and owns 2 production plants in Poland as well as one in Vietnam. The pillars of the company's development are foreign expansion and investments in increasing the production of medication in Poland and in innovation.


For more than 20 years, the company has been conducting its own innovative R&D work, for which it has allocated PLN 2.1 billion since 2001. Adamed is currently implementing projects in three therapeutic areas: oncology, diabetology and neuropsychiatry. The company's intellectual property is protected by over 200 patents in most countries around the world, and its portfolio includes over 500 products.


Each year, the company produces over 2.5 billion tablets offered in over 70 markets around the world. It ensures general access to therapy for millions of patients in Poland and many other countries.


Adamed Pharma has 9 representative offices. A consistently implemented development strategy based on innovation and foreign expansion has made the company a well-known and international brand today. For years, it has been observing a gradual increase in sales of its products - both in terms of volume and value. Currently, foreign operations account for a third of its business, and development plans assume that it will be 55%.